Nucleoside analogues in the treatment of chronic hepatitis B. (Q33988066)

30 July 2017

1 reference

title

Nucleoside analogues in the treatment of chronic hepatitis B. (English)

1 reference

30 July 2017

1 reference

N Leung

1

1 reference

30 July 2017

1 May 2000

1 reference

Journal of Gastroenterology and Hepatology

30 July 2017

1 reference

30 July 2017

15 Suppl

1 reference

30 July 2017

E53-60

1 reference

Randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection

30 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02103.X

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02103.X

Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02103.X

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02103.X

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02103.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02103.X

The polarized hepatic human/rat hybrid WIF 12-1 and WIF-B cells communicate efficiently in vitro via connexin 32-constituted gap junctions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02103.X

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02103.X

Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02103.X

Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02103.X

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02103.X

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02103.X

Clinical impact of lamivudine resistance in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02103.X

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02103.X

Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02103.X

10.1046/J.1440-1746.2000.02103.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10921383